Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PROPYLTHIOURACIL IMPURITY A CRS (15 MG)

PROPYLTHIOURACIL IMPURITY A CRS (15 MG)

ND

DISCOVER
PROPYLENE GLYCOL MONOCAPRYLATE CRS (600 MG)

PROPYLENE GLYCOL MONOCAPRYLATE CRS (600 MG)

ND

DISCOVER
CEFOXITIN FOR PEAK IDENTIFICATION A CRS (15 MG)

CEFOXITIN FOR PEAK IDENTIFICATION A CRS (15 MG)

ND

DISCOVER
BUPIVACAINE IMPURITY D CRS (0.001 MG)

BUPIVACAINE IMPURITY D CRS (0.001 MG)

ND

DISCOVER
ALPHA-TOCOPHERYL ACETATE FOR SYSTEM SUITABILITY CRS (100 MG)

ALPHA-TOCOPHERYL ACETATE FOR SYSTEM SUITABILITY CRS (100 MG)

ND

DISCOVER
SALBUTAMOL FOR PEAK IDENTIFICATION CRS (20 MG)

SALBUTAMOL FOR PEAK IDENTIFICATION CRS (20 MG)

ND

DISCOVER
BUPIVACAINE CRS (20 MG)

BUPIVACAINE CRS (20 MG)

ND

DISCOVER
DABIGATRAN ETEXILATE IMPURITYA CRS (12 MG)

DABIGATRAN ETEXILATE IMPURITYA CRS (12 MG)

ND

DISCOVER
DABIGATRAN ETEXILATE IMPURITYB CRS (10 MG)

DABIGATRAN ETEXILATE IMPURITYB CRS (10 MG)

ND

DISCOVER
DABIGATRAN ETEXILATE IMPURITYC CRS (10 MG)

DABIGATRAN ETEXILATE IMPURITYC CRS (10 MG)

ND

DISCOVER
PIMOZIDE FOR SYSTEM SUITABILITY CRS (15 MG)

PIMOZIDE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
TRIMETHOPRIM FOR PEAK IDENTIFICATION CRS (1.001 MG)

TRIMETHOPRIM FOR PEAK IDENTIFICATION CRS (1.001 MG)

NA

DISCOVER